BioSpace News Archive

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of trading and hold a webcast and conference call to discuss the results of its Phase 2, double-masked, head-to-head study of VOS 0.2% versus Restasis

Monash University biospectroscopists have been issued a US patent for the diagnostic technology they hope will one day help doctors to diagnose and treat patients much faster than current pathology methods.

Today the Novo Holdings REPAIR Impact Fund announces that three additional investments were made in late 2018. In the first year of operation, a total of €18 million was invested in four companies developing innovative novel anti-infective therapies

VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced today they will be leading a pan-industry effort to independently analyze and report all patient-level safety data associated with paclitaxel-eluting devices for the treatment of peripheral artery disease (PAD) above the knee.

“I’m a nurse practitioner and I thought there could be a better treatment option for people with severe allergies,” said an inventor, from Allentown, N.J., “so I invented patent pending DEY SPRAY.”

Lipogems is an increasingly popular option among patients suffering from an orthopedic issue - knee, shoulder, other joints - who, for one reason or another, aren’t candidates for a major invasive operation

What would you do for one million dollars? Would you climb Mount Everest? Tightrope walk across the Grand Canyon? Face your greatest fear? Diamond Dallas Page (known as DDP) is not asking you to do any of these things… he simply wants you to Own Your Life!

Please be advised that Dan Vandal, Parliamentary Secretary to the Minister of Indigenous Services, will announce two community infrastructure projects in Lac-Simon.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Teladoc Health, Inc. from March 3, 2016 through December 5, 2018, inclusive (the “Class Period”) of the important February 11, 2019 lead plaintiff deadline in the class action.

Revenue cycle management (RCM) reinvention has come into focus in the healthcare industry as providers look for innovative ways to cope with the growing array of health plans with deep contractual and network complexities and almost constantly changing rules and requirements.